Company: MYGN
Filing Date: 2025-05-07
Form Type: 10-Q
Source: 0000899923-25-000048
Chunk: 64

Company: MYRIAD GENETICS INC
Filing Date: 2025-05-07
Form: 10-Q
Item: Part I, Item 8
Chunk 64
---
 letter of credit exposure. Such cash dominion period will end when availability has remained in excess of the greater of (i) $12.5 million and (ii) 15% of the lesser of the maximum commitment amount and the borrowing base for a period of 45 consecutive days and no event of default is continuing.

8.PREFERRED AND COMMON STOCKHOLDERS' EQUITY

The Company is authorized to issue up to 5.0 million shares of preferred stock, par value $0.01 per share. There were no shares of preferred stock outstanding at March 31, 2025.The Company is authorized to issue up to 150.0 million shares of common stock, par value $0.01 per share. There were 92.2 million shares of common stock issued and outstanding at March 31, 2025.Shares of common stock issued and outstandingThree months endedMarch 31,(in millions)20252024Beginning common stock issued and outstanding91.3 89.9 Common stock issued upon exercise of options, vesting of restricted stock units, and purchases under employee stock purchase plan0.9 0.6 Common stock issued and outstanding at end of period92.2 90.5 Basic earnings per share is computed based on the weighted-average number of shares of common stock outstanding. Diluted earnings per share is computed based on the weighted-average number of shares of common stock, including the dilutive effect of common stock equivalents, outstanding. In periods when the Company has a net loss, stock awards are excluded from the calculation of diluted net loss per share as their inclusion would have an antidilutive effect.The following is a reconciliation of the denominators of the basic and diluted earnings per share (“EPS”) computations:Three months endedMarch 31,(in millions)20252024Denominator:Weighted-average shares outstanding used to compute basic EPS91.4 89.9 Effect of dilutive shares— — Weighted-average shares outstanding and dilutive securities used to compute diluted EPS91.4 89.9 

13

Table of Contents

Certain outstanding options and restricted stock units (“RSUs”) were excluded from the computation of diluted earnings per share because the effect would have been anti-dilutive. These potential dilutive shares of common stock, which may be dilutive to future diluted earnings per share, are as follows:Three months endedMarch 31,(in millions)20252024Anti-dilutive options and RSUs excluded from EPS